Amphipathic Peptide Nanocomplex for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nano carriers for nucleic acid delivery, such as viral vectors, cationic lipids, and polymers, face limitations like low transfection efficiency, high cytotoxicity, and complex synthesis procedures, making them unsuitable for clinical use, particularly for delivering large cargoes like plasmid DNA.
Innovation Solution
Development of a nanocomplex using modified amphipathic peptides (Mgpe-3, Mgpe-4, Mgpe-9, and Mgpe-10) derived from Human Protein phosphatase 1E, optimized for hydrophobicity, charge, and amphipathicity, which form stable complexes with DNA and facilitate efficient cellular uptake and endosomal escape.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids or polymers are used as nano carriers for nucleic acid delivery, then transfection efficiency is improved, but cytotoxicity increases and synthesis complexity increases
Solution Approach 1:
The patent modifies the amino acid composition and charge ratio of peptides to optimize transfection efficiency while reducing cytotoxicity. Specific parameters such as peptide length, hydrophobicity, and positive charge density are tuned to achieve the desired balance between delivery efficiency and cellular compatibility
Solution Approach 2:
The patent employs amphipathic peptides that combine both hydrophobic and hydrophilic regions, creating a composite structure that mimics natural membrane interactions. This dual-nature design allows the peptide to effectively complex with nucleic acids while maintaining biocompatibility and reducing toxicity compared to purely cationic materials
2Reliability
If cationic polymers are used as nano carriers, then transfection efficiency is improved, but synthesis complexity and lack of control over physico-chemical properties increase
Solution Approach 1:
The patent uses short peptides (12-30 amino acids) that can be synthesized using standard solid-phase peptide synthesis methods, avoiding the need for complex polymerization procedures. These peptides are easier to produce with controlled properties compared to synthetic cationic polymers, and can be readily modified or replaced
Solution Approach 2:
The patent achieves precise control over peptide properties by modifying amino acid sequences at the molecular level. Parameters such as charge density, hydrophobicity, and amphipathicity are controlled through selective amino acid substitution, providing uniform and reproducible physico-chemical properties that are difficult to achieve with polymer systems
3Ease of operation
If amphipathic peptides are used for nucleic acid delivery, then cellular uptake and endosomal escape are improved, but delivery efficiency for large cargoes like plasmid DNA decreases
Solution Approach 1:
The patent combines the amphipathic structure (for membrane interaction) with sufficient positive charge capacity (for nucleic acid condensation) in a single peptide molecule. This merging of functions allows the peptide to effectively handle both small and large nucleic acid cargoes by forming stable nanocomplexes while maintaining cellular uptake capabilities
Solution Approach 2:
The patent optimizes peptide parameters including increasing peptide length within the 12-30 amino acid range, adjusting the ratio of hydrophobic to hydrophilic residues, and tuning the total positive charge to achieve optimal condensation of large plasmid DNA while preserving the amphipathic structure needed for cellular uptake and endosomal escape
4Reliability
If high hydrophobicity and positive charge are used in amphipathic peptides, then DNA condensation and cellular uptake are improved, but cellular toxicity increases
Solution Approach 1:
The patent precisely controls the balance between hydrophobicity and positive charge by selecting specific amino acid compositions. The peptides are designed with moderate hydrophobicity (through controlled hydrophobic residue content) and optimized positive charge density (through arginine and lysine content), achieving effective DNA condensation while maintaining cellular compatibility
Solution Approach 2:
The amphipathic peptide structure creates a composite functional design where hydrophobic regions provide membrane interaction capability while hydrophilic charged regions provide nucleic acid binding. This composite architecture distributes the functional demands, allowing effective DNA condensation without requiring excessive overall charge or hydrophobicity that would cause toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocomplexes achieve high transfection efficiency with minimal cytotoxicity and serum stability, comparable to or exceeding commercial agents like Cellfectin and Lipofectamine 2000, while effectively delivering both plasmid DNA and small RNA across various cell lines.
Implementation Method 1
positive charged amino acids of the peptide condense DNA to form these nano complexes
Implementation Method 2
The hydrophobic amino acids of the peptide interact with membrane and help in cellular uptake of the nanocomplex
Data Source
Figure 1A~1E
Figure 2A~2E
Figure 3A~3E
AI summary
The present invention relates to a nanocomplex useful for efficient transfection and delivery of biomolecules comprising amphipathic peptide sequence. The invention more particularly relates to the development of amphipathic peptides for the delivery of biomolecules to the eukaryotic cells. These peptide based vectors can form stable nanocomplex with biomolecules mainly with nucleic acids and can deliver it efficiently to cells. The complexation can be done non-covalently with small as well as large biomolecules.